Cargando…
An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease
The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteri...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461820/ https://www.ncbi.nlm.nih.gov/pubmed/37639428 http://dx.doi.org/10.1371/journal.pone.0283489 |
_version_ | 1785097916546809856 |
---|---|
author | Meunier, Marine Spillmann, Adrian Rousseaux, Christel Schwamborn, Klaus Hanson, Melissa |
author_facet | Meunier, Marine Spillmann, Adrian Rousseaux, Christel Schwamborn, Klaus Hanson, Melissa |
author_sort | Meunier, Marine |
collection | PubMed |
description | The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients. |
format | Online Article Text |
id | pubmed-10461820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-104618202023-08-29 An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease Meunier, Marine Spillmann, Adrian Rousseaux, Christel Schwamborn, Klaus Hanson, Melissa PLoS One Research Article The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients. Public Library of Science 2023-08-28 /pmc/articles/PMC10461820/ /pubmed/37639428 http://dx.doi.org/10.1371/journal.pone.0283489 Text en © 2023 Meunier et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Meunier, Marine Spillmann, Adrian Rousseaux, Christel Schwamborn, Klaus Hanson, Melissa An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
title | An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
title_full | An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
title_fullStr | An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
title_full_unstemmed | An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
title_short | An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
title_sort | oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461820/ https://www.ncbi.nlm.nih.gov/pubmed/37639428 http://dx.doi.org/10.1371/journal.pone.0283489 |
work_keys_str_mv | AT meuniermarine anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT spillmannadrian anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT rousseauxchristel anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT schwambornklaus anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT hansonmelissa anoralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT meuniermarine oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT spillmannadrian oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT rousseauxchristel oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT schwambornklaus oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease AT hansonmelissa oralcholeravaccineinthepreventionandortreatmentofinflammatoryboweldisease |